# Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14

> **NCT03404856** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Orpha Labs** · enrollment: 5 (estimated)

## Conditions studied

- Glycogen Storage Disease, Type 14

## Interventions

- **DRUG:** ORL-1G - D-galactose

## Key facts

- **NCT ID:** NCT03404856
- **Lead sponsor:** Orpha Labs
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-10-31
- **Primary completion:** 2019-10-31
- **Final completion:** 2019-10-31
- **Target enrollment:** 5 (ESTIMATED)
- **Last updated:** 2019-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03404856

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03404856, "Study of ORL-1G (D-galactose) in Patients With Glycogen Storage Disease Type 14". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03404856. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*